CEACAM5 and prostate cancer: Currently, glycosylated proteins have become one of the most common cancer biomarkers in the clinic, such as alpha-fetoprotein (AFP) for hepatocellular carcinoma [67], carcinoembryonic antigen (CEA) for colon cancer [68] and prostate specific antigen (PSA) for prostate cancer [69].